408
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

, , , , , , & show all
Pages 2959-2961 | Received 08 Aug 2014, Accepted 14 Feb 2015, Published online: 12 May 2015
 

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal. Medical writing and editing services were provided by BlueMomentum, an Ashfield Company, and supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.

Supplementary material available online

Supplementary Tables I–IV to be found online at http://informahealthcare.com/doi/abs/10.3109/10428194.2015.1020801.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.